Movement Alert｜WUXI BIO Rises 4.75% in Regular Trading, CXO Sector Momentum Continues Amid Acquisition and Earnings Catalysts

Market Focus

08/10

On August 10, WUXI BIO rose 4.75% in regular trading, trading at HK$47.34/share, with turnover of HK$217 million.

The rally extends gains following the company's announcement on August 7 of a definitive agreement to acquire Transcenta Therapeutics' process development and production base in Hangzhou, China. The facility is expected to enhance WUXI BIO's integrated end-to-end service capabilities covering drug substance development, production, and drug product manufacturing, with the transaction anticipated to close in Q3. CEO Dr. Zhisheng Chen stated the acquisition further strengthens the company's comprehensive service offering.

Additionally, the broader CXO sector continues to trade strongly after peer WuXi AppTec reported robust first-half results, with revenue of RMB 28.9 billion (+38.93% YoY) and adjusted net profit surging 89.39% YoY. Market participants also maintain positive expectations ahead of WUXI BIO's board meeting scheduled for August 25 to review interim results. Within the Life Sciences Tools and Services sector, WUXI APPTEC rose 4.52%, XTALPI rose 8.41%, INSILICO rose 7.35%, and GENSCRIPT BIO rose 2.7%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1120647811"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120647811\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120647811?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 09:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120647811","market":"hk","top_or_hot":-1,"title":"Movement Alert｜WUXI BIO Rises 4.75% in Regular Trading, CXO Sector Momentum Continues Amid Acquisition and Earnings Catalysts","media":"Market Focus","content":"<p><p>On August 10, WUXI BIO rose 4.75% in regular trading, trading at HK$47.34/share, with turnover of HK$217 million.</p><p>The rally extends gains following the company's announcement on August 7 of a definitive agreement to acquire Transcenta Therapeutics' process development and production base in Hangzhou, China. The facility is expected to enhance WUXI BIO's integrated end-to-end service capabilities covering drug substance development, production, and drug product manufacturing, with the transaction anticipated to close in Q3. CEO Dr. Zhisheng Chen stated the acquisition further strengthens the company's comprehensive service offering.</p><p>Additionally, the broader CXO sector continues to trade strongly after peer WuXi AppTec reported robust first-half results, with revenue of RMB 28.9 billion (+38.93% YoY) and adjusted net profit surging 89.39% YoY. Market participants also maintain positive expectations ahead of WUXI BIO's board meeting scheduled for August 25 to review interim results. Within the Life Sciences Tools and Services sector, WUXI APPTEC rose 4.52%, XTALPI rose 8.41%, INSILICO rose 7.35%, and GENSCRIPT BIO rose 2.7%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WUXI BIO Rises 4.75% in Regular Trading, CXO Sector Momentum Continues Amid Acquisition and Earnings Catalysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WUXI BIO Rises 4.75% in Regular Trading, CXO Sector Momentum Continues Amid Acquisition and Earnings Catalysts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-10 09:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 10, WUXI BIO rose 4.75% in regular trading, trading at HK$47.34/share, with turnover of HK$217 million.</p><p>The rally extends gains following the company's announcement on August 7 of a definitive agreement to acquire Transcenta Therapeutics' process development and production base in Hangzhou, China. The facility is expected to enhance WUXI BIO's integrated end-to-end service capabilities covering drug substance development, production, and drug product manufacturing, with the transaction anticipated to close in Q3. CEO Dr. Zhisheng Chen stated the acquisition further strengthens the company's comprehensive service offering.</p><p>Additionally, the broader CXO sector continues to trade strongly after peer WuXi AppTec reported robust first-half results, with revenue of RMB 28.9 billion (+38.93% YoY) and adjusted net profit surging 89.39% YoY. Market participants also maintain positive expectations ahead of WUXI BIO's board meeting scheduled for August 25 to review interim results. Within the Life Sciences Tools and Services sector, WUXI APPTEC rose 4.52%, XTALPI rose 8.41%, INSILICO rose 7.35%, and GENSCRIPT BIO rose 2.7%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"","article_id":"1120647811","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120647811","pubTimestamp":1786325571,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 10, WUXI BIO rose 4.75% in regular trading, trading at HK$47.34/share, with turnover of HK$217 million.The rally extends gains following the company's announcement on August 7 of a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02269":"药明生物"},"translate_title":"走势提醒|药明生物常规交易上涨4.75%，CXO板块在收购和盈利催化剂下势头持续","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"On August 10, WUXI BIO rose 4.75% in regular trading, trading at HK$47.34/share, with turnover of HK$217 million.The rally extends gains following the company's announcement on August 7 of a definitive agreement to acquire Transcenta Therapeutics' process development and production base in Hangzhou, China. The facility is expected to enhance WUXI BIO's integrated end-to-end service capabilities covering drug substance development, production, and drug product manufacturing, with the transaction anticipated to close in Q3. CEO Dr. Zhisheng Chen stated the acquisition further strengthens the company's comprehensive service offering.Additionally, the broader CXO sector continues to trade strongly after peer WuXi AppTec reported robust first-half results, with revenue of RMB 28.9 billion (+38.93% YoY) and adjusted net profit surging 89.39% YoY. Market participants also maintain positive expectations ahead of WUXI BIO's board meeting scheduled for August 25 to review interim results. Within the Life Sciences Tools and Services sector, WUXI APPTEC rose 4.52%, XTALPI rose 8.41%, INSILICO rose 7.35%, and GENSCRIPT BIO rose 2.7%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}